Glenmark's PDE-4 inhibitor moves into Phase IIb after promising early data
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals has initiated Phase IIb dose-finding studies in asthma and rheumatoid arthritis for its oral phosphodiesterase-4 (PDE-4) inhibitor, revamilast (GRC 4039), in Europe and Asia, following promising early data with the compound from UK trials.